# Neurocrine Biosciences Inc: financial statements, quarterly

NBIX · Nasdaq · CIK 914475 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nbix.md) · [Financials](/companies/nbix/financials.md) · [Filings](/companies/nbix/filings.md) · [Insiders](/companies/nbix/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nbix/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [499](/filings/0000914475-24-000211.md) | [515 d](/filings/0000914475-26-000007.md) | [515](/filings/0000914475-25-000100.md) | [590](/filings/0000914475-25-000158.md) | [622](/filings/0000914475-25-000181.md) | [628 d](/filings/0000914475-26-000007.md) | [573](/filings/0000914475-26-000026.md) | [688](/filings/0000914475-26-000037.md) | [795](/filings/0000914475-25-000181.md) | [806 d](/filings/0000914475-26-000007.md) | [815](/filings/0000914475-26-000026.md) | [959](/filings/0000914475-26-000037.md) |
| Cost of revenue | $m | [11.2](/filings/0000914475-24-000211.md) | [8.5 d](/filings/0000914475-26-000007.md) | [7.5](/filings/0000914475-25-000100.md) | [9.2](/filings/0000914475-25-000158.md) | [8.0](/filings/0000914475-25-000181.md) | [9.3 d](/filings/0000914475-26-000007.md) | [9.2](/filings/0000914475-26-000026.md) | [11.3](/filings/0000914475-25-000158.md) | [14.0](/filings/0000914475-25-000181.md) | [17.6 d](/filings/0000914475-26-000007.md) | [13.8](/filings/0000914475-26-000026.md) | not reported |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [204](/filings/0000914475-24-000211.md) | [219 d](/filings/0000914475-26-000007.md) | [243](/filings/0000914475-25-000100.md) | [242](/filings/0000914475-25-000158.md) | [234](/filings/0000914475-25-000181.md) | [288 d](/filings/0000914475-26-000007.md) | [277](/filings/0000914475-26-000026.md) | [286](/filings/0000914475-26-000037.md) | [292](/filings/0000914475-25-000181.md) | [302 d](/filings/0000914475-26-000007.md) | [319](/filings/0000914475-26-000026.md) | [440](/filings/0000914475-26-000037.md) |
| Operating income | $m | [141](/filings/0000914475-24-000211.md) | [150 d](/filings/0000914475-26-000007.md) | [99.3](/filings/0000914475-25-000100.md) | [145](/filings/0000914475-25-000158.md) | [184](/filings/0000914475-25-000181.md) | [142 d](/filings/0000914475-26-000007.md) | [23.6](/filings/0000914475-26-000026.md) | [146](/filings/0000914475-26-000037.md) | [239](/filings/0000914475-25-000181.md) | [211 d](/filings/0000914475-26-000007.md) | [193](/filings/0000914475-26-000026.md) | [152](/filings/0000914475-26-000037.md) |
| Interest expense | $m | [1.1](/filings/0000914475-23-000073.md) | [1.1 d](/filings/0000914475-24-000054.md) | [1.1](/filings/0000914475-24-000117.md) | not reported | not reported | not reported | not reported | [0.0](/filings/0000914475-26-000037.md) | not reported | not reported | not reported | [2.9](/filings/0000914475-26-000037.md) |
| Income tax | $m | [32.5](/filings/0000914475-24-000211.md) | [50.5 d](/filings/0000914475-26-000007.md) | [(8.9)](/filings/0000914475-25-000100.md) | [33.6](/filings/0000914475-25-000158.md) | [60.5](/filings/0000914475-25-000181.md) | [59.5 d](/filings/0000914475-26-000007.md) | [6.8](/filings/0000914475-26-000026.md) | [52.0](/filings/0000914475-26-000037.md) | [82.3](/filings/0000914475-25-000181.md) | [85.7 d](/filings/0000914475-26-000007.md) | [48.9](/filings/0000914475-26-000026.md) | [17.8](/filings/0000914475-26-000037.md) |
| Net income | $m | [83.1](/filings/0000914475-24-000211.md) | [148 d](/filings/0000914475-26-000007.md) | [43.4](/filings/0000914475-25-000100.md) | [65.0](/filings/0000914475-25-000158.md) | [130](/filings/0000914475-25-000181.md) | [103 d](/filings/0000914475-26-000007.md) | [7.9](/filings/0000914475-26-000026.md) | [108](/filings/0000914475-26-000037.md) | [210](/filings/0000914475-25-000181.md) | [154 d](/filings/0000914475-26-000007.md) | [198](/filings/0000914475-26-000026.md) | [144](/filings/0000914475-26-000037.md) |
| Diluted EPS | $ per share | [0.82](/filings/0000914475-24-000211.md) | not reported | [0.42](/filings/0000914475-25-000100.md) | [0.63](/filings/0000914475-25-000158.md) | [1.24](/filings/0000914475-25-000181.md) | not reported | [0.08](/filings/0000914475-26-000026.md) | [1.06](/filings/0000914475-26-000037.md) | [2.04](/filings/0000914475-25-000181.md) | not reported | [1.91](/filings/0000914475-26-000026.md) | [1.39](/filings/0000914475-26-000037.md) |
| Basic EPS | $ per share | [0.85](/filings/0000914475-24-000211.md) | not reported | [0.43](/filings/0000914475-25-000100.md) | [0.64](/filings/0000914475-25-000158.md) | [1.28](/filings/0000914475-25-000181.md) | not reported | [0.08](/filings/0000914475-26-000026.md) | [1.09](/filings/0000914475-26-000037.md) | [2.11](/filings/0000914475-25-000181.md) | not reported | [1.97](/filings/0000914475-26-000026.md) | [1.43](/filings/0000914475-26-000037.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [294](/filings/0000914475-24-000211.md) | [251](/filings/0000914475-25-000037.md) | [396](/filings/0000914475-25-000100.md) | [140](/filings/0000914475-25-000158.md) | [349](/filings/0000914475-25-000181.md) | [233](/filings/0000914475-26-000007.md) | [194](/filings/0000914475-26-000026.md) | [264](/filings/0000914475-26-000037.md) | [340](/filings/0000914475-25-000181.md) | [713](/filings/0000914475-26-000037.md) | [267](/filings/0000914475-26-000026.md) | [332](/filings/0000914475-26-000037.md) |
| Current assets | $m | [1,650](/filings/0000914475-23-000073.md) | [1,607](/filings/0000914475-25-000037.md) | [1,799](/filings/0000914475-24-000117.md) | [1,670](/filings/0000914475-24-000181.md) | [1,877](/filings/0000914475-24-000211.md) | [1,725](/filings/0000914475-26-000007.md) | [1,638](/filings/0000914475-25-000100.md) | [1,749](/filings/0000914475-25-000158.md) | [2,158](/filings/0000914475-25-000181.md) | [2,523](/filings/0000914475-26-000037.md) | [2,436](/filings/0000914475-26-000026.md) | [1,638](/filings/0000914475-26-000037.md) |
| Total assets | $m | [2,848](/filings/0000914475-23-000073.md) | [3,251](/filings/0000914475-25-000037.md) | [3,472](/filings/0000914475-24-000117.md) | [3,305](/filings/0000914475-24-000181.md) | [3,535](/filings/0000914475-24-000211.md) | [3,719](/filings/0000914475-26-000007.md) | [3,688](/filings/0000914475-25-000100.md) | [3,890](/filings/0000914475-25-000158.md) | [4,266](/filings/0000914475-25-000181.md) | [4,632](/filings/0000914475-26-000037.md) | [4,906](/filings/0000914475-26-000026.md) | [5,359](/filings/0000914475-26-000037.md) |
| Current liabilities | $m | [692](/filings/0000914475-23-000073.md) | [655](/filings/0000914475-25-000037.md) | [713](/filings/0000914475-24-000117.md) | [399](/filings/0000914475-24-000181.md) | [430](/filings/0000914475-24-000211.md) | [508](/filings/0000914475-26-000007.md) | [523](/filings/0000914475-25-000100.md) | [546](/filings/0000914475-25-000158.md) | [638](/filings/0000914475-25-000181.md) | [743](/filings/0000914475-26-000037.md) | [832](/filings/0000914475-26-000026.md) | [875](/filings/0000914475-26-000037.md) |
| Total liabilities | $m | [846](/filings/0000914475-23-000073.md) | [1,019](/filings/0000914475-25-000037.md) | [1,086](/filings/0000914475-24-000117.md) | [796](/filings/0000914475-24-000181.md) | [816](/filings/0000914475-24-000211.md) | [1,129](/filings/0000914475-26-000007.md) | [1,152](/filings/0000914475-25-000100.md) | [1,196](/filings/0000914475-25-000158.md) | [1,262](/filings/0000914475-25-000181.md) | [1,378](/filings/0000914475-26-000037.md) | [1,499](/filings/0000914475-26-000026.md) | [1,666](/filings/0000914475-26-000037.md) |
| Shareholders' equity | $m | [2,002](/filings/0000914475-24-000211.md) | [2,232](/filings/0000914475-26-000007.md) | [2,386](/filings/0000914475-25-000158.md) | [2,509](/filings/0000914475-25-000181.md) | [2,719](/filings/0000914475-25-000181.md) | [2,590](/filings/0000914475-26-000037.md) | [2,536](/filings/0000914475-26-000037.md) | [2,694](/filings/0000914475-26-000037.md) | [3,004](/filings/0000914475-25-000181.md) | [3,253](/filings/0000914475-26-000037.md) | [3,407](/filings/0000914475-26-000037.md) | [3,694](/filings/0000914475-26-000037.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [212 d](/filings/0000914475-24-000211.md) | [124 d](/filings/0000914475-26-000007.md) | [130](/filings/0000914475-25-000100.md) | [64.6 d](/filings/0000914475-25-000158.md) | [158 d](/filings/0000914475-25-000181.md) | [243 d](/filings/0000914475-26-000007.md) | [64.8](/filings/0000914475-26-000026.md) | [102 d](/filings/0000914475-26-000037.md) | [228 d](/filings/0000914475-25-000181.md) | [388 d](/filings/0000914475-26-000007.md) | [146](/filings/0000914475-26-000026.md) | [136 d](/filings/0000914475-26-000037.md) |
| Capital expenditure | $m | [7.6 d](/filings/0000914475-24-000211.md) | [5.4 d](/filings/0000914475-26-000007.md) | [11.2](/filings/0000914475-25-000100.md) | [11.6 d](/filings/0000914475-25-000158.md) | [8.1 d](/filings/0000914475-25-000181.md) | [7.3 d](/filings/0000914475-26-000007.md) | [10.7](/filings/0000914475-26-000026.md) | [12.5 d](/filings/0000914475-26-000037.md) | [13.2 d](/filings/0000914475-25-000181.md) | [(2.4) d](/filings/0000914475-26-000007.md) | [9.1](/filings/0000914475-26-000026.md) | [7.8 d](/filings/0000914475-26-000037.md) |
| Share repurchases | $m | not reported | not reported | [0.0](/filings/0000914475-25-000100.md) | [0.0 d](/filings/0000914475-25-000158.md) | [0.0 d](/filings/0000914475-25-000181.md) | [300 d](/filings/0000914475-26-000007.md) | [150](/filings/0000914475-26-000026.md) | [17.7 d](/filings/0000914475-26-000037.md) | [0.0 d](/filings/0000914475-25-000181.md) | [0.0 d](/filings/0000914475-26-000007.md) | [54.0](/filings/0000914475-26-000026.md) | [12.0 d](/filings/0000914475-26-000037.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [99.0](/filings/0000914475-23-000073.md) | [97.1](/filings/0000914475-24-000117.md) | [100](/filings/0000914475-24-000181.md) | [101](/filings/0000914475-24-000211.md) | [104](/filings/0000914475-25-000100.md) | [104](/filings/0000914475-25-000158.md) | [104](/filings/0000914475-25-000181.md) | [103](/filings/0000914475-26-000026.md) | [101](/filings/0000914475-26-000037.md) | [103](/filings/0000914475-25-000181.md) | [103](/filings/0000914475-26-000026.md) | [104](/filings/0000914475-26-000037.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 101,649,181 at 2026-07-22, from the cover of the [10-Q filed 2026-07-31](/filings/0000914475-26-000037.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:28 ET. No prices; not investment advice.